Duract (bromfenac) was on the market less than a year

July 1998

Duract (bromfenac) was on the market less than a year.

This NSAID worked well for acute pain, but got pulled becauseof reports of severe hepatic failure in patients who used Duract formore than 10 days or had pre-existing hepatic disease.

In fact, its labeling had a black-box warning not to take itfor more than 10 days because of the risk of hepatic toxicity.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

grapefruit juices can increase levels of Mevacor (lovastatin)
Cardiology "Hypertension Optimal Treatment" study
Cardiology Posicor's removal from the market
Vitamin E seems to reduce the risk of prostate cancer
7-keto DHEA
Women's Health Prometrium, the first commercially available form of ORAL micronized progesterone
Hepatitis C Hepatitis C is a growing problem
Gastroenterology patients can reduce embarrassing flatulence odor by using Pepto-Bismol (bismuth subsalicylate)
Diabetes the NIH is no longer using Rezulin (troglitazone) in their large Diabetes Prevention Study
Diabetes replacing SureStep meters made before August '97
Neurology & Pain Duract (bromfenac) was on the market less than a year
Transdermal Patches whether it's okay to cut patches in half
best way to prevent and treat mosquito bites
Pediatrics shorter course of antibiotics for uncomplicated cases of acute otitis media (AOM)

Duract (bromfenac) was on the market less than a year

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents